- Q3 revenue grew 27% year-over-year driven by 61,500 clinical cases.
- Full-year 2026 revenue guidance raised to $1.04B–$1.05B (up 28% to 29%).
- Continued positive net earnings per share reported for the quarter.
Bullish AI Sentiment (+6.5 / 10)
Signal #136354 · SEC 8-K
$CAI SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $CAI filing catalyst
Why did $CAI trigger an AI stock catalyst alert?
$CAI triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.5/10). Headline: Caris Life Sciences Reports Q3 2026 Revenue Growth of 27% and Raises Full-Year Guidance. Key points: - Q3 revenue grew 27% year-over-year driven by 61,500 clinical cases. - Full-year 2026 revenue guidance raised to $1.04B–$1.05B (up 28% to 29%). - Continued positive net earnings per share reported for the quarter.
How did $CAI stock react after the SEC filing?
After the SEC 8-K for $CAI, observed market reaction: T0 price $33.22. Past moves do not guarantee future results.
Where can I get real-time $CAI SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $CAI via Telegram and the VIP Web Terminal from €10/month.